Weekly Fungal Diagnostics Research Update – 24 August 2026
This week’s fungal diagnostics literature is unusually coherent: several papers point in the same direction, towards faster molecular diagnosis, more practical point-of-care testing and better interpretation of antifungal susceptibility results.
A new review in Medical Mycology provides a useful overview of where fungal diagnostics are heading, while new studies this week show how panfungal PCR, nanopore sequencing, antigen testing and epidemiological cutoff values are already beginning to address long-standing diagnostic gaps.
The future of fungal diagnostics
Southern-Thomas R, Goyal S, Wild AL, Stone N.
The Future of Fungal Diagnostics: What’s next in laboratory testing for invasive fungal infection?
Medical Mycology. Published 22 August 2026.
Invasive fungal infections remain difficult to diagnose quickly and accurately. Traditional culture-based methods are relatively slow and can lack sensitivity, while histopathology and microscopy often depend on obtaining suitable clinical samples.
This review examines newer approaches intended to improve diagnosis, including molecular techniques, biomarkers and point-of-care assays. It also discusses the practical barriers that determine whether a promising diagnostic method actually reaches routine clinical use, including cost, accessibility, standardisation and laboratory infrastructure.
Why this matters: The challenge in fungal diagnostics is no longer simply inventing more sensitive tests. New methods also have to be reproducible, affordable, interpretable and usable in the settings where patients are actually being diagnosed.
Panfungal PCR on tissue: stronger evidence from a major meta-analysis
Filippidis P, El Khoury C, Cruciani M, et al.
Diagnostic performance of panfungal PCR on tissue specimens for the diagnosis of invasive fungal diseases: a systematic review and meta-analysis of the Fungal PCR Initiative (FPCRI).
Journal of Clinical Microbiology. Published 21 August 2026.
Culture from tissue remains an important part of diagnosing invasive fungal disease, but sensitivity is limited, particularly when patients have already received antifungal therapy.
This systematic review and meta-analysis examined the diagnostic performance of panfungal PCR on tissue specimens. These assays typically target conserved fungal ribosomal regions such as 18S, 28S or ITS, followed by sequencing to identify the organism.
The study included both fresh or frozen tissue and formalin-fixed paraffin-embedded specimens, and confirms that panfungal PCR can provide clinically useful fungal identification when fungal elements are seen histologically or culture is negative.
Why this matters: Tissue samples are often difficult or risky to obtain. Molecular testing can increase the diagnostic yield from precious biopsy material and may identify fungi that would otherwise remain unrecognised.
Nanopore sequencing detects fungal bloodstream infections before cultures turn positive
Yoshioka I, Uchida M, Kusuya Y, et al.
Random PCR-based nanopore whole-genome sequencing enables pre-positivity detection of fungal bloodstream infections.
Microbiology Spectrum. Published 21 August 2026.
Bloodstream fungal infections, particularly candidemia, can be associated with substantial morbidity and mortality, and delays in identification can delay appropriate antifungal treatment.
This study developed a random-PCR nanopore whole-genome sequencing workflow designed to identify fungal pathogens directly from blood-culture samples before the automated culture system had signalled positive.
The researchers validated the approach using real-time nanopore sequencing, demonstrating the potential for earlier species identification from samples that had not yet reached conventional blood-culture positivity.
Why this matters: If validated further, this type of workflow could shorten the time between blood sampling and fungal identification, potentially allowing earlier targeted treatment and infection-control decisions.
Important practical questions remain, including cost, workflow complexity, contamination control and the amount of sequencing required before a result can be reported confidently.
Histoplasma urine antigen: lateral-flow testing compared with EIA
da Silva DG, Lemke PAL, Paredes RES, et al.
Urine detection of Histoplasma antigens among symptomatic people living with HIV in Mato Grosso do Sul, Brazil: a comparative study of EIA and Lateral Flow Assay.
Medical Mycology. Published 20 August 2026.
Disseminated histoplasmosis remains a major cause of illness and death in people with advanced HIV disease, particularly in endemic regions. Rapid diagnosis is therefore extremely important.
This study compared two urine antigen methods in 241 symptomatic people living with HIV: the IMMY Clarus Histoplasma galactomannan enzyme immunoassay and the MiraVista Histoplasma lateral-flow assay.
Lateral-flow tests have an important potential advantage because they can provide a rapid result with substantially less laboratory infrastructure than conventional enzyme immunoassays.
Why this matters: A well-performing urine lateral-flow assay could improve access to rapid histoplasmosis diagnosis in settings where laboratory capacity is limited and delays in treatment carry a high risk.
New epidemiological cutoff values for Purpureocillium lilacinum
Smith DJ, Winkler ML, Dufresne PJ, et al.
Establishment of epidemiological cutoff values against Purpureocillium lilacinum.
Journal of Clinical Microbiology. Published 21 August 2026.
Purpureocillium lilacinum is an environmental mould capable of causing opportunistic infection, including invasive disease.
One challenge for laboratories is that formal clinical antifungal breakpoints are not available for many uncommon moulds.
This international study performed antifungal susceptibility testing on P. lilacinum isolates to establish epidemiological cutoff values (ECVs). ECVs help distinguish the normal wild-type susceptibility distribution from isolates that may have acquired or intrinsic mechanisms associated with unusually high MICs.
Why this matters: ECVs do not tell clinicians whether a particular drug will definitely succeed or fail in an individual patient. However, they provide laboratories with an important framework for detecting non-wild-type isolates and monitoring emerging resistance.
Provisional antifungal cutoff values for Trichophyton mentagrophytes and T. interdigitale
Zheng H, Xie W, Song Y, et al.
In vitro susceptibility and provisional epidemiological cutoff values for eight antifungal agents against Trichophyton mentagrophytes and Trichophyton interdigitale: a multicenter study from China.
Journal of Clinical Microbiology. Published 21 August 2026.
Dermatophyte infections are extremely common, but interpretation of antifungal susceptibility testing remains difficult because established clinical breakpoints are lacking for many species and antifungal agents.
This multicentre study measured susceptibility to eight antifungal drugs and proposed provisional epidemiological cutoff values for Trichophyton mentagrophytes and T. interdigitale.
Why this matters: Resistant dermatophyte infections are an increasing concern internationally. Better-defined susceptibility distributions can help laboratories detect unusual resistance patterns and support surveillance while clinical breakpoints continue to develop.
What stands out this week?
This week’s papers highlight several recurring themes in modern fungal diagnostics:
- Culture is no longer enough on its own. Panfungal PCR and sequencing are increasingly important when conventional methods are slow or insensitive.
- Speed matters. Nanopore sequencing before conventional blood-culture positivity illustrates the growing push towards diagnosis in hours rather than days.
- Point-of-care testing is becoming increasingly realistic. Histoplasma urine lateral-flow assays could bring fungal diagnostics closer to patients in settings with limited laboratory capacity.
- Susceptibility results need better interpretation. Epidemiological cutoff values are particularly valuable for uncommon fungi and dermatophytes where formal clinical breakpoints remain unavailable.
The broader message from this week’s literature is that fungal diagnostics are moving from a relatively small number of conventional techniques towards a more integrated approach combining culture, molecular testing, antigen detection, sequencing and structured susceptibility interpretation.
This weekly research update summarises recently published fungal-diagnostics research for laboratory and clinical professionals. Inclusion does not imply endorsement of a particular assay or diagnostic platform. New methods require appropriate validation, quality assurance and interpretation within the clinical context before routine implementation.